This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
7
All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
Novo Nordisk Investigational Site
Groningen, Netherlands
Total amount of [3H]-somapacitan related material excreted in urine (% of dose)
Time frame: Assessed up to 35 days after trial product administration
Total amount of [3H]-somapacitan related material excreted in faeces (% of dose)
Time frame: Assessed up to 35 days after trial product administration
Total amount of [3H]-somapacitan related material excreted in expired air (% of dose)
Time frame: Assessed up to 35 days after trial product administration
Total recovery of administered 3H label (sum of urine, faeces and expired air)
Time frame: Assessed up to 36 days after trial product administration
Blood to plasma ratio of [3H]-somapacitan related material
Time frame: Assessed up to 36 days after trial product administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.